Oxford BioMedica develops strategic development plan with the commercialisation of TroVax

20-Mar-2008

Oxfordshire Bioscience Network (OBN), organisers of the forth coming Bio Trinity 2008 conference, has confirmed Peter Nolan, SVP Commercial Development at Oxford BioMedica as a lead speaker on this years programme. Mr Nolan will discuss the company's partnership with sanofi-aventis to develop and commercialise TroVax(r) for the treatment and prevention of a number of cancer indications. This follows the announcement that the TRIST trial successfully completed patient enrolment.

TroVax(r) is Oxford BioMedica's lead cancer immunotherapy. Based on the broad distribution of the 5T4 tumour antigen, TroVax(r) has potential application in a wide range of solid tumours, including renal, colorectal, lung, breast and prostate cancer. Earlier this month Oxford BioMedica announced that it has successfully completed patient enrolment in the Phase III TRIST study. Over 690 patients have been randomised to-date and a sufficient number of additional patients are being screened for inclusion such that the total enrolment is expected to slightly exceed the target of 700 patients. Over 100 sites in the USA, European Union and Eastern Europe have recruited patients into the trial. The trial started in November 2006; recruitment has been completed on schedule and final results from the study are anticipated in the first half of 2009.

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance